Special Issue "Vaccines: Uptake and Equity in Times of the COVID-19 Pandemic"
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 108787
As societies and, more specifically, healthcare delivery systems have reorganized and adapted during the COVID-19 pandemic, there has been a de-emphasis in many important healthcare activities, including routine life-course immunizations. Childhood and booster immunizations have been disrupted or delayed in some instances. Drops in vaccination rates risk long-term consequences, and it is possible that loss of vaccine protection may disproportionately impact vulnerable and disadvantaged populations.
It is unclear at this moment whether measures to improve vaccine uptake prior to the COVID-19 pandemic will now be sustained or whether they need to be adjusted. At the same time, vaccine providers need to familiarize themselves with the best ways to generate catch-up programs and new ways to serve their communities in these unprecedented times.
With procurement mechanisms evolving around pandemic vaccines—including vaccines still in development to protect from SARS-CoV2—new questions will arise around scalability, equity, and access. These considerations will add to the existing challenges in vaccine uptake.
Experts disagree on the impact of a prospective pandemic vaccine on overall vaccine acceptance in the wider community. At the same time, simultaneous improvements in diagnostics, antibody treatments, and antivirals may also influence the sense of urgency to vaccinate.
This Special Issue invites subject matter experts on vaccines, public health, bioethics, vaccine research and development, anthropology, global health, risk analysis, economics, clinical medicine, basic science, and information technology to weigh in on this timely topic. We seek original manuscripts, reviews, position papers, and contributions from basic and clinical science, modeling/epidemiology, and the humanities that will provide novel ideas and scientific evidence to this important discussion. Lessons learned from the past and current health crises for pandemic preparedness in the future should also be considered.
Prof. Dr. Barbara Rath
Editorial Board Member
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pandemic preparedness
- antiviral therapy
- vaccine confidence
- risk communication
- vaccine hesitancy
- public health